

Special Issue

Frontiers in Phage Therapy

Message from the Guest Editors

With regard to the therapeutic use of bacteriophages in humans, there have been two key developments that: (a) the increasing appearance of antibiotic-resistant bacterial strains, including the so-called “superbugs”, and (b) the recognition of the importance of the role that the human microbiota plays in maintaining the normal homeostatic equilibrium of human organisms, and of the ways in which human microbiota imbalances (so-called dysbiosis) influence not only the onset but the development of a variety of human diseases.

Consequently, there are two new roles that bacteriophages may be called upon to perform: (1) directly acting agents against infectious diseases for which antibiotics are no longer effective, and (2) microbiota-modulating agents capable of selectively favoring the colonization and establishment of microbial populations in gut. This Special Issue focuses on highlighting the most recent successful applications of bacteriophage-based therapeutic approaches.

Guest Editors

Prof. Dr. Tomás González Villa

Department of Microbiology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Coruna, Spain

Prof. Dr. Vicente Notario

Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA

Deadline for manuscript submissions

closed (28 February 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/85033

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)